The neuroendocrine architecture orchestrating human physiological adaptation to homeostatic disruption relies heavily on a precise cascade of chemical messengers. Central to this survival apparatus is the adrenocorticotropic hormone-releasing factor, universally recognized as the principal neurovascular trigger initiating systemic stress reactivity across vertebrate species. By coordinating both autonomic arousal and behavioral adaptations, this neuropeptide represents a critical biological bridge linking perceived psychological environmental challenges with peripheral endocrine execution.
ACTH-Releasing Factor
1. Concise Definition
ACTH-releasing factor (commonly referred to as corticotropin-releasing factor, corticotropin-releasing hormone, or CRH) is a 41-amino-acid peptide neurohormone synthesized primarily within the parvocellular neurons of the paraventricular nucleus of the hypothalamus. Its primary biological function is the stimulation of the synthesis and hypophyseal secretion of adrenocorticotropic hormone (adrenocorticotropic hormone, ACTH) from the anterior pituitary gland, thereby serving as the primary neuroendocrine initiator of the hypothalamic-pituitary-adrenal axis.
Beyond its classical endocrine role within the hypophyseal portal circulation, ACTH-releasing factor functions as an active neuromodulator throughout extrahypothalamic networks in the central nervous system, including the amygdaloid complex, bed nucleus of the stria terminalis, and locus coeruleus. In these regional anatomical circuits, it orchestrates autonomic, electrophysiological, behavioral, and immunological responses to physical and psychological stressors, modulating fear conditioning, vigilance, cognitive appraisal, and emotional valence.
2. Etymology & Linguistic Origin
The nomenclature of ACTH-releasing factor derives from its targeted physiological activity and structural constituents. The acronym “ACTH” represents “adrenocorticotropic hormone,” rooted in the Latin ad (toward), renes (kidneys), the Greek kortex (outer bark or shell), and tropos (turning, tending toward, or having an affinity for), describing a biochemical agent oriented toward stimulating the adrenal cortex. The word “releasing” derives from the Old French relaissier and Latin relaxare (to unfasten, loosen, or discharge).
Historically denoted in physiological literature as “ACTH-releasing factor” (CRF) prior to its complete structural identification, the molecule assumed the designation “corticotropin-releasing hormone” (CRH) once its definitive chemical structure was isolated and purified. While “factor” was conventionally applied to crude or partially uncharacterized tissue extracts demonstrating biological activity, “hormone” entered standard biochemical parlance after peptide sequencing confirmed its distinct endogenous existence. Despite this nomenclature shift, both terms remain used synonymously across neuroendocrinology, behavioral neuroscience, and psychoneuroimmunology.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed in International Phonetic Alphabet (IPA) notation as /ˌeɪ.siː.tiːˈeɪtʃ rɪˈliː.sɪŋ ˈfæk.tər/. In its alternative form, Corticotropin-Releasing Factor is pronounced as /ˌkɔːr.tɪ.koʊˈtroʊ.pɪn rɪˈliː.sɪŋ ˈfæk.tər/.
Grammatical Form: Compound noun phrase, masculine/neuter inanimate noun construct. It regularly serves as a syntactic nominal phrase or an adjectival modifier in molecular combinations (e.g., “ACTH-releasing factor receptor antagonist,” “ACTH-releasing factor-positive parvocellular neurons”). Common standard abbreviations include CRF, CRH, and CRF-41.
4. Detailed Conceptual Explanation
To understand ACTH-releasing factor requires analyzing its dual operational classification: an endocrine neurohormone driving systemic peripheral endocrine homeostasis, and an integral central neurotransmitter driving localized synaptic transmission. In its classical hypophysiotropic function, parvocellular neurosecretory neurons situated within the paraventricular nucleus (PVN) of the hypothalamus synthesize pro-CRF, processing the precursor polypeptide into its active 41-amino-acid peptide form. Upon activation by psychological or systemic physiological perturbations, these neurons release the peptide from neurosecretory axon terminals into the primary capillary plexus of the hypophyseal portal system at the median eminence.
Once transported across the vascular fenestrations to the anterior lobe of the pituitary gland (adenohypophysis), the peptide selectively binds to high-affinity Corticotropin-Releasing Factor Receptor Type 1 (CRF1) located on the plasma membrane of corticotrope cells. This binding stimulates a G-protein-coupled cascade—primarily via Gαs—activating adenylyl cyclase, which increases intracellular cyclic adenosine monophosphate (cAMP) and mobilizes protein kinase A (PKA). The resulting phosphorylation of transcription factors, such as the cAMP response element-binding protein (CREB), upregulates transcription of the pro-opiomelanocortin (POMC) gene while simultaneously stimulating exocytosis of stored adrenocorticotropic hormone (ACTH) into the general systemic venous circulation.
Beyond the hypothalamic-pituitary-adrenal (hypothalamic-pituitary-adrenal axis) axis, ACTH-releasing factor acts within widespread central neural networks. Intrinsic CRF-expressing neurons are distributed throughout the central nucleus of the amygdala, the bed nucleus of the stria terminalis, the neocortex, the hippocampus, and brainstem autonomic nuclei including the locus coeruleus and the nucleus of the solitary tract. In these extrahypothalamic regions, CRF acts as an excitatory neuromodulator that coordinates autonomic adjustments, such as elevating mean arterial pressure, increasing heart rate, accelerating respiratory frequency, and suppressing non-essential vegetative processes including digestion, feeding, and reproductive behavior.
The actions of ACTH-releasing factor are tightly regulated by endogenous high-affinity corticotropin-releasing factor-binding protein (CRF-BP). Circulating and membrane-associated CRF-BP sequesters the free neuropeptide, limiting its bioavailability and preventing continuous, unrestrained activation of downstream receptors. Dysregulation within this delicate equilibrium—whether through excessive ligand synthesis, impaired receptor downregulation, or insufficient binding-protein buffering—is implicated in numerous physiological and affective pathologies.
5. Historical Development
The quest to identify the elusive substance triggering pituitary adrenocorticotropic secretion began in the mid-twentieth century. Following Hans Selye’s landmark characterization of the general adaptation syndrome in 1936, endocrinologists recognized that the central nervous system must possess a mechanism to convey stress-related signals directly to the anterior pituitary gland, which lacks direct motor innervation. In 1955, neuroendocrinologists Roger Guillemin and Murray Saffran independently confirmed the presence of a distinct neurohumoral substance in hypothalamic explants capable of releasing ACTH in vitro, giving birth to the operational term “corticotropin-releasing factor.”
Despite this early functional confirmation, structural isolation eluded researchers for nearly three decades due to the minute quantities of the peptide present in mammalian brain tissue and the biochemical instability of peptide fractions. The breakthrough occurred in 1981, when Wylie Vale and his research team at the Salk Institute for Biological Studies successfully isolated, purified, sequenced, and synthesized the 41-amino-acid peptide from thousands of ovine hypothalamus specimens. Shortly thereafter, the human and rat cDNA sequences were cloned, establishing that mammalian ACTH-releasing factor is preserved with high evolutionary homology.
Throughout the late 1980s and 1990s, research shifted toward mapping receptor pharmacology and identifying additional endogenous ligands. Molecular cloning revealed two distinct G-protein-coupled receptor subtypes: CRF1 (cloned in 1993) and CRF2 (cloned in 1995). Concurrently, related mammalian peptides belonging to the CRF family—termed urocortin 1, urocortin 2, and urocortin 3—were isolated, confirming that the ACTH-releasing factor system operates as an intricate family of diverse ligands and receptors regulating stress adaptation, metabolic equilibrium, and cardiovascular function.
6. Theoretical Foundations
The functional dynamics of ACTH-releasing factor are grounded in classic and contemporary biological theories of physiological regulation, beginning with Claude Bernard’s formulation of the milieu intérieur and Walter Cannon’s refinement of homeostasis. Under homoeostatic models, ACTH-releasing factor acts as an essential sensor and homeostatic transducer: whenever physiological parameters deviate from set ranges (e.g., during acute hypoglycemia, hemorrhage, or systemic infection), parvocellular neurons release CRF to mobilize energy stores via downstream glucocorticoids, restoring equilibrium.
As stress neurobiology incorporated chronic behavioral challenges, neuroscientists Peter Sterling and Joseph Eyer, along with Bruce McEwen, formulated the paradigm of allostasis—achieving stability through physiological change. In allostatic theory, ACTH-releasing factor serves as the master biological coordinator that initiates an allostatic state. Acute elevation of CRF mediates adaptive physiological and behavioral adjustments; however, chronic or repeated overproduction imposes “allostatic load” and “allostatic overload.” Sustained receptor activation precipitates multisystem wear-and-tear, manifesting in hippocampal dendritic atrophy, prefrontal cortical synaptic loss, chronic hypertension, and metabolic dysfunction.
Furthermore, evolutionary psychology and neurobiological ethology contextualize ACTH-releasing factor through the lens of adaptive survival strategies. The peptide coordinates an integrated behavioral transition away from resource-gathering behaviors (foraging, sleeping, and mating) toward hypervigilant defense maneuvers (freezing, escape, fight-or-flight, and risk assessment). While this behavioral shift provides a survival advantage in the face of immediate physical predation, its protracted activation in response to chronic modern psychosocial stressors is maladaptive, predisposing individuals to major affective and anxiety disorders.
7. Key Components, Types & Dimensions
The neurobiology of ACTH-releasing factor encompasses multiple interacting ligands, receptor subtypes, structural variants, and regulatory carrier proteins:
- CRF Peptide (CRF-41): The primary 41-amino-acid residue ligand characterized by an alpha-helical secondary structure, responsible for initiating the classical neuroendocrine endocrine cascade via the hypophyseal portal vasculature.
- Corticotropin-Releasing Factor Receptor Type 1 (CRF1): A class B secretin-like G-protein-coupled receptor widely expressed throughout the anterior pituitary corticotropes, cerebral cortex, cerebellum, amygdala, and hippocampus. It displays high binding affinity for CRF and mediates neuroendocrine activation, heightened anxiety, vigilance, and behavioral stress responses.
- Corticotropin-Releasing Factor Receptor Type 2 (CRF2): A second class B GPCR that exists in distinct spliced isoforms (CRF2α, CRF2β, CRF2γ) with predominant localization in subcortical structures (lateral septum, ventromedial hypothalamus), peripheral cardiovascular tissue, and gastrointestinal tracts. It exhibits lower affinity for CRF but high affinity for urocortins, often functioning as a dampener or recovery modulator following initial stress surges.
- The Urocortin Peptide Family: Paralogous endogenous peptide family members including Urocortin 1 (Ucn1), Urocortin 2 (Ucn2), and Urocortin 3 (Ucn3), which selectively or preferentially activate CRF1 and CRF2 to regulate autonomic, cardiovascular, metabolic, and delayed stress recovery pathways.
- CRF-Binding Protein (CRF-BP): A 37-kDa soluble glycoprotein expressed extracellularly and intracellularly that binds circulating and synaptic CRF and Urocortin 1 with an affinity equal to or exceeding that of CRF receptors, neutralizing their functional bioavailability.
- Intracellular Signaling Pathways: Downstream enzymatic cascades coupled to CRF receptors, predominantly involving the Gαs-cAMP-PKA pathway, alongside secondary mobilization of phospholipase C (PLC), inositol trisphosphate (IP3), intracellular calcium, and mitogen-activated protein kinase (MAPK) pathways.
8. Examples & Illustrative Cases
To demonstrate the functional role of ACTH-releasing factor in clinical and everyday contexts, consider the following physiological and psychological scenarios:
- Acute Physiological Challenge (Systemic Hypoglycemia): When an individual receives an accidental excess dose of insulin, circulating blood glucose drops precipitously. Chemoreceptive brainstem structures sense this metabolic deficit and transmit ascending catecholaminergic projections to the PVN. Parvocellular neurons immediately secrete ACTH-releasing factor into the median eminence. Within seconds, CRF triggers anterior pituitary corticotropes to discharge ACTH into peripheral circulation, which stimulates the adrenal cortex to produce cortisol. Cortisol accelerates hepatic gluconeogenesis and decreases peripheral glucose uptake, restoring physiological blood sugar levels.
- Acute Psychosocial Stress (Public Speaking): An individual facing an unexpected, evaluative audience experiences cognitive apprehension. Limbic circuits—including the basolateral amygdala and prefrontal cortex—process this threat and stimulate extrahypothalamic and hypothalamic CRF networks. Central CRF increases locus coeruleus firing, elevating systemic norepinephrine, heart rate, and cutaneous vasoconstriction (cold, sweaty palms). Simultaneously, the PVN drives hypophyseal portal release of CRF, elevating plasma ACTH and salivary cortisol within 15 to 30 minutes, sharpening alertness and focus for immediate performance.
- Chronic Neuropathological Case (Post-Traumatic Stress Disorder): A combat veteran exposed to prolonged traumatic events presents with chronic hyperarousal, intrusive flashbacks, insomnia, and exaggerated startle reflexes. Lumbar punctures reveal persistently elevated levels of ACTH-releasing factor in the cerebrospinal fluid, despite normal or blunted circulating systemic baseline cortisol levels. This extrahypothalamic CRF hypersecretion drives sustained hyperexcitability within the central nucleus of the amygdala and locus coeruleus, illustrating how central dysregulation of this neuropeptide can dissociate from classic peripheral feedback loops, maintaining chronic psychiatric distress.
9. Measurement & Assessment
Assessing ACTH-releasing factor concentrations and functional integrity requires sophisticated biochemical, biological, and neuroimaging modalities tailored to clinical or preclinical settings:
In human clinical research, direct measurement of CRF in peripheral blood plasma is of limited diagnostic utility because the peptide is rapidly degraded by endopeptidases, bound by circulating CRF-BP, and largely confined within the portal vasculature, failing to cross the blood-brain barrier in substantial quantities. Consequently, clinical researchers analyze cerebrospinal fluid (CSF) obtained via lumbar puncture to measure central nervous system peptide production. Quantitative quantification is performed using high-sensitivity Enzyme-Linked Immunosorbent Assays (ELISA) or Radioimmunoassays (RIA), often combined with high-performance liquid chromatography (HPLC) to isolate peptide fragments.
Dynamic neuroendocrine function is clinically evaluated using the Dexamethasone/CRH Challenge Test. In this neuroendocrine protocol, a synthetic glucocorticoid (dexamethasone) is administered overnight to suppress pituitary-adrenal activity via negative feedback. The following afternoon, an intravenous bolus of synthetic human or ovine ACTH-releasing factor is administered, and serial blood draws measure plasma ACTH and cortisol concentrations over two hours. An exaggerated hormonal release indicates impaired central glucocorticoid receptor sensitivity and disrupted negative feedback, a diagnostic marker frequently observed in patients with melancholic major depressive disorder.
In preclinical basic science, investigators employ quantitative real-time PCR (RT-qPCR) and in situ hybridization histochemistry to measure Crh mRNA expression within microdissected brain regions. Cellular distribution is visualized using immunohistochemistry, immunofluorescence, and automated confocal microscopy. Furthermore, modern neuroscience utilizes genetically engineered transgenic mice expressing Cre-recombinase under the control of the Crh promoter (CRH-Cre lines), facilitating precise optogenetic excitation or chemogenetic inhibition of distinct CRF-positive neuronal circuits in real time during behavioral testing.
10. Applications & Practical Significance
The translational value of ACTH-releasing factor spans multiple medical, psychological, and pharmacological domains:
Psychiatry and Psychopharmacology: Due to the central role of CRF in generating anxiety-like states, hypervigilance, and anhedonia, major pharmaceutical initiatives have sought to synthesize small-molecule, lipophilic CRF1 receptor antagonists capable of penetrating the blood-brain barrier (e.g., antalarmin, CP-154,526, emicerfont). Although clinical trials in human major depressive disorder and generalized anxiety disorder yielded mixed outcomes—largely due to liver enzyme elevations, suboptimal bioavailability, and biological patient heterogeneity—modulating the CRF system remains a major target for treating treatment-resistant depression, post-traumatic stress disorder, and social anxiety disorder.
Addiction and Substance Dependence: ACTH-releasing factor plays an established role in the neurobiology of addiction, particularly during the transition from recreational use to chronic dependency. Preclinical models developed by George Koob demonstrate that during drug withdrawal (from alcohol, opioids, cocaine, or nicotine), CRF transmission surges within the extended amygdala, including the central nucleus of the amygdala and the bed nucleus of the stria terminalis. This surge drives profound negative affect, irritability, dysphoria, and physical discomfort, creating a powerful drive for stress-induced relapse through negative reinforcement mechanisms.
Gastroenterology and Somatic Medicine: Receptors for ACTH-releasing factor are densely expressed throughout the enteric nervous system and colonic mucosal architecture. Activation of central and peripheral CRF receptors by stress alters gastrointestinal motility, increases intestinal epithelial permeability (“leaky gut”), induces visceral hypersensitivity, and drives degranulation of mast cells. Consequently, CRF signaling is a primary target in the pathophysiology of Irritable Bowel Syndrome (IBS) and stress-exacerbated inflammatory bowel diseases.
11. Research & Empirical Evidence
Extensive empirical studies have elucidated the mechanisms through which ACTH-releasing factor regulates physiology and behavior. Following Vale and colleagues’ original 1981 purification, early experiments established that intracerebroventricular (ICV) microinjections of synthetic CRF into laboratory rodents produced dose-dependent behavioral phenotypes mirroring natural fear: elevated freezing, suppressed exploratory locomotion in open-field arenas, decreased consumption of food in novel environments, and increased acoustic startle responses. These behavioral effects persisted even in hypophysectomized or adrenalectomized animals, demonstrating that central CRF acts independently of peripheral pituitary-adrenal hormones.
In clinical neurobiology, Charles Nemeroff and colleagues published landmark papers throughout the 1980s and 1990s demonstrating elevated concentrations of CRF in the cerebrospinal fluid of drug-free patients with major depressive disorder compared to healthy control subjects. Subsequent post-mortem histopathological analyses revealed marked upregulation of CRF-immunoreactive neurons and elevated CRH gene expression within the PVN of depressed individuals, coupled with a compensatory downregulation of CRF1 receptor density in the frontal cortex, suggesting chronic neuroendocrine hypersecretion.
In neuroepigenetics, research spearheaded by Michael Meaney and colleagues showed that maternal care in rodents (variations in pup licking and grooming) directly alters the epigenetic programming of the Crh gene and hippocampal glucocorticoid receptors in offspring. Pups receiving low levels of maternal care exhibited DNA hypomethylation at the Crh promoter, resulting in life-long elevations in ACTH-releasing factor expression, persistent hyperreactivity to stress, and elevated anxiety-like behaviors across adulthood. These findings confirmed that environmental conditions during critical developmental windows can fine-tune the central ACTH-releasing factor rheostat via lasting epigenetic modifications.
12. Cultural & Cross-Cultural Considerations
While the molecular structure and biological machinery of ACTH-releasing factor are evolutionarily conserved across human populations, the expression of its activity is influenced by cultural, environmental, and social contexts. The biological set-point and sensitivity of the central CRF system develop through real-time interactions with environmental stressors, including childhood trauma, systemic marginalization, economic insecurity, and collective adversity.
Anthropological and transcultural psychiatric research indicates that the physiological experience of stress-induced CRF activation is characterized by varying somatic and psychological manifestations across cultural groups. In Western psychiatric models, overactivation of the extended amygdala-CRF circuitry is commonly described through affective and cognitive terms: internal anxiety, sadness, existential dread, or catastrophic worry. Conversely, in many non-Western populations, identical neurobiological stress states may be experienced and described somatically—such as gastric burning, physical heart constriction, widespread bodily tension, or sensations of heat, which correspond directly to the dense distribution of CRF receptors throughout the enteric nervous system and autonomic centers.
Furthermore, cross-cultural studies examining historical trauma and intergenerational stress suggest that collective epigenetic marks altering the sensitivity of the ACTH-releasing factor cascade may be transmitted across generations. Populations exposed to collective historical trauma exhibit altered neuroendocrine set-points, highlighting that biological stress markers must be evaluated in conjunction with broad socioeconomic, historical, and cultural conditions.
13. Criticisms, Debates & Limitations
Despite vast empirical literature, several theoretical debates, clinical limitations, and scientific controversies continue to surround ACTH-releasing factor:
The Clinical Translation Paradox: The most significant disappointment in translational stress neurobiology has been the failure of synthetic CRF1 receptor antagonists in late-phase human psychiatric clinical trials. Despite strong preclinical efficacy in suppressing rodent anxiety and depressive behaviors, compounds developed by major pharmaceutical companies regularly failed to outperform placebos in double-blind clinical trials. Researchers debate whether this failure stems from redundant neurobiological pathways in the human brain, insufficient receptor occupancy in targeted limbic nuclei, or biological heterogeneity within broad Diagnostic and Statistical Manual of Mental Disorders (DSM) categories, which combine biochemically distinct subtypes of depression and anxiety.
Functional Receptor Oppositional Models: A continuous scientific debate concerns the contrasting roles of CRF1 and CRF2 receptors. Early models suggested that CRF1 exclusively mediates anxiogenesis and stress initiation, whereas CRF2 functions solely as an anxiolytic, stress-terminating receptor. However, subsequent empirical data have demonstrated that CRF2 activation within specific brain nuclei (such as the dorsal raphe nucleus or lateral septum) can actually promote anxiety, hyperarousal, and depressive-like phenotypes depending on prior stress history, ambient serotonin tone, and regional splice-variant localization.
Peripheral versus Central Compartmentalization: Methodological limitations arise from the biological dissociation between central and peripheral compartments. Peripheral measurements of plasma CRF often provide little insight into intra-parenchymal synaptic levels within subcortical limbic circuits. This compartmentalization complicates the clinical utility of peripheral assays as reliable biomarkers for complex psychological disorders.
14. Related Terms & Distinctions
To establish diagnostic and biochemical clarity, ACTH-releasing factor must be systematically distinguished from related molecules, precursors, and functional partners:
- Corticotropin-Releasing Hormone (CRH): Synonymous with ACTH-releasing factor; the formal biochemical designation used interchangeably to describe the active 41-amino-acid peptide.
- Adrenocorticotropic Hormone (ACTH): The direct downstream endocrine target of CRF; a 39-amino-acid polypeptide synthesized by pituitary corticotropes and released into peripheral systemic circulation to stimulate glucocorticoid synthesis in the adrenal cortex.
- Vasopressin (Arginine Vasopressin / AVP): A separate 9-amino-acid hypothalamic nonapeptide synthesized within magnocellular and parvocellular PVN neurons that acts synergistically with ACTH-releasing factor to stimulate pituitary ACTH secretion via V1b receptors, particularly during chronic sustained stress.
- Pro-opiomelanocortin (POMC): The massive precursor polypeptide synthesized in anterior pituitary corticotrope cells that is cleaved enzymatically into ACTH, beta-endorphin, and melanocyte-stimulating hormones upon stimulation by ACTH-releasing factor.
- Urocortins (Ucn1, Ucn2, Ucn3): Endogenous mammalian peptides related to CRF that share structural homology but exhibit distinct receptor affinities, playing primary roles in autonomic balance, appetite regulation, and cardiovascular homeostasis rather than classical pituitary-adrenal activation.
- Cortisol / Corticosterone: The ultimate peripheral end-product glucocorticoids synthesized by the adrenal cortex (cortisol in humans, corticosterone in rodents) that circulate back to the brain to exert potent inhibitory negative feedback upon hypothalamic CRF and pituitary ACTH transcription.
15. Summary / Key Takeaways
ACTH-releasing factor (CRF/CRH) remains one of the most critical neuroendocrine molecules discovered in modern physiology. Synthesized in the parvocellular neurons of the hypothalamic paraventricular nucleus, it initiates the neuroendocrine response to systemic and psychological threat by stimulating pituitary ACTH release, driving downstream corticosteroid synthesis. Beyond this classical endocrine role, extrahypothalamic CRF networks distributed across the amygdala, cortex, and brainstem orchestrate autonomic arousal, fear behaviors, vigilance, and homeostatic defense adjustments.
While essential for acute survival, chronic overactivation of the ACTH-releasing factor signaling apparatus contributes to the development of major affective disorders, anxiety pathology, addiction relapse, and stress-related gastrointestinal conditions. Ongoing research using precision optogenetics, structural cryo-electron microscopy, and cell-type-specific pharmacology continues to uncover the nuances of this neuropeptide system, paving the way for targeted interventions capable of restoring neuroendocrine equilibrium in stress-related human disease.
References
- Bale, T. L., & Vale, W. W. (2004). CRF and CRF receptors: Organizing autonomic, neuroendocrine and behavioral responses to stress. Dialogues in Clinical Neuroscience, 6(1), 11–22. https://doi.org/10.31887/DCNS.2004.6.1/tbale
- Dedic, N., Chen, A., & Deussing, J. M. (2018). The CRF family of neuropeptides and their receptors: Mediators of the central stress response. Current Topics in Behavioral Neurosciences, 39, 3–31. https://doi.org/10.1007/7854_2017_26
- Koob, G. F. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Research, 1314, 3–14. https://doi.org/10.1016/j.brainres.2009.09.006
- Nemeroff, C. B. (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Molecular Psychiatry, 1(4), 336–342.
- Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science, 213(4514), 1394–1397. https://doi.org/10.1126/science.6267699